Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in the June 30, 2010 issue of Managing Intellectual Property titled “Federal Circuit to re-hear biotech cases post-Bilski.” Brinckerhoff discusses the Supreme Court’s decision to grant certiorari, and then vacate and remand biotech patent case Prometheus v Mayo in light of the decision issued in Bilski v. Kappos. She states that the contested patents in Prometheus should survive since the Federal Circuit has already found that they meet the machine-or-transformation test, but notes that the Bilski decision includes some troubling points for biotech and pharmaceutical patents. She adds that assessing whether a particular patent might promote or impede innovation as a way of determining patent eligibility could be a slippery slope.
People
Related News
March 13, 2026
In the News
Chris Babcock and Chris Converse on Wave of Companies Moving to Texas
Foley & Lardner LLP partners Chrisopher Babcock and Chris Converse commented on the widening trend of companies reincorporating to Texas in the Houston Business Journal article, “Texas law changes could spark wave of corporate redomestication proposals."
March 12, 2026
In the News
Louis Lehot Explores M&A's Growing Blitzhire Phenomenon
Foley & Lardner LLP partner Louis Lehot authors article on the emergence of blitzhires in the Mergers & Acquisitions article, “Blitzhires: The New Fast-Moving M&A Deal.”
March 10, 2026
In the News
Aaron Maguregui Shares Insights on Shadow AI Risks in Health Care
Foley & Lardner LLP partner Aaron Maguregui was quoted in the Part B News article, “Do you need AI policy? Experts suggest guardrails as 'shadow AI' spreads,” discussing the emerging risks of unsanctioned 'shadow AI' use by clinicians and the need to establish robust AI governance.